A comparison of therapeutic oxygen versus medical air for the treatment of central sleep apnea in infants with Prader-Willi syndrome; A proof-of-concept randomized crossover trial.

Sleep MedJun 9, 2026 (epub)
Clinical ResearchPediatricsPulmonology

Haley Fishman, Emma Wen, Colin Massicotte et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized crossover trial evaluated the effects of supplemental oxygen versus medical air on central sleep apnea (CSA) in infants with Prader-Willi syndrome (PWS). Among 10 infants, supplemental oxygen significantly reduced the central apnea-hypopnea index (CAHI) by an adjusted difference of -7.7 events/hr (p = 0.048), while improving oxygen saturation levels.

Key findings

  • Supplemental oxygen reduced CAHI by an adjusted difference of -7.7 events/hr compared to medical air.
  • Oxygen saturation nadir increased by +8.2% with supplemental oxygen (p < 0.001).
  • Mean transcutaneous CO2 was modestly lower with oxygen, showing a decrease of -2.2 mmHg (p = 0.024).
  • No significant changes were observed in sleep architecture or obstructive apnea-hypopnea index.

Why it matters

The findings suggest that supplemental oxygen is an effective first-line therapy for managing central sleep apnea in infants with Prader-Willi syndrome, potentially improving patient outcomes without adverse effects on carbon dioxide levels or sleep quality.

Source

PubMed · PMID 42287973

Published in Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.